288 related articles for article (PubMed ID: 23095522)
21. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
22. Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
Lemos C; Kathmann I; Giovannetti E; Calhau C; Jansen G; Peters GJ
Br J Cancer; 2009 Apr; 100(7):1120-7. PubMed ID: 19277036
[TBL] [Abstract][Full Text] [Related]
23. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
Tang R; Cohen S; Perrot JY; Faussat AM; Zuany-Amorim C; Marjanovic Z; Morjani H; Fava F; Corre E; Legrand O; Marie JP
BMC Cancer; 2009 Jun; 9():199. PubMed ID: 19549303
[TBL] [Abstract][Full Text] [Related]
24. A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.
Strouse JJ; Ivnitski-Steele I; Khawaja HM; Perez D; Ricci J; Yao T; Weiner WS; Schroeder CE; Simpson DS; Maki BE; Li K; Golden JE; Foutz TD; Waller A; Evangelisti AM; Young SM; Chavez SE; Garcia MJ; Ursu O; Bologa CG; Carter MB; Salas VM; Gouveia K; Tegos GP; Oprea TI; Edwards BS; Aubé J; Larson RS; Sklar LA
J Biomol Screen; 2013 Jan; 18(1):26-38. PubMed ID: 22923785
[TBL] [Abstract][Full Text] [Related]
25. Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.
Strouse JJ; Ivnitski-Steele I; Waller A; Young SM; Perez D; Evangelisti AM; Ursu O; Bologa CG; Carter MB; Salas VM; Tegos G; Larson RS; Oprea TI; Edwards BS; Sklar LA
Anal Biochem; 2013 Jun; 437(1):77-87. PubMed ID: 23470221
[TBL] [Abstract][Full Text] [Related]
26. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O
Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.
Hiwase DK; Saunders VA; Nievergall E; Ross DD; White DL; Hughes TP
Haematologica; 2013 Jun; 98(6):896-900. PubMed ID: 23065516
[TBL] [Abstract][Full Text] [Related]
28. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells.
Quiney C; Billard C; Faussat AM; Salanoubat C; Kolb JP
Leuk Lymphoma; 2007 Aug; 48(8):1587-99. PubMed ID: 17701591
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
30. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Lainey E; Wolfromm A; Marie N; Enot D; Scoazec M; Bouteloup C; Leroy C; Micol JB; De Botton S; Galluzzi L; Fenaux P; Kroemer G
Oncogene; 2013 Sep; 32(37):4331-42. PubMed ID: 23085751
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of SCN5A overcomes ABC transporter-mediated multidrug resistance in acute myeloid leukemia through promoting apoptosis.
Xu K; Zhuang XX; Shi XW
Expert Rev Hematol; 2024; 17(1-3):87-94. PubMed ID: 38230679
[TBL] [Abstract][Full Text] [Related]
32. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
33. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
[TBL] [Abstract][Full Text] [Related]
35. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
36. EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives.
Colabufo NA; Contino M; Niso M; Berardi F; Leopoldo M; Perrone R
Front Biosci (Landmark Ed); 2011 Jan; 16(5):1811-23. PubMed ID: 21196266
[TBL] [Abstract][Full Text] [Related]
37. The role of ABC transporters in clinical practice.
Leonard GD; Fojo T; Bates SE
Oncologist; 2003; 8(5):411-24. PubMed ID: 14530494
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
[TBL] [Abstract][Full Text] [Related]
39. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
40. Rapid detection of ABC transporter interaction: potential utility in pharmacology.
Robey RW; Lin B; Qiu J; Chan LL; Bates SE
J Pharmacol Toxicol Methods; 2011; 63(3):217-22. PubMed ID: 21112407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
